-
Acalatinib, veneclax, and octuzumab have excellent efficacy in newly diagnosed CLL
Time of Update: 2022-02-23
Fixed-duration therapy with the BCL-2 inhibitor veneclax combined with the anti-CD20 antibody octuzumab is also effective, but high-risk cytogenetics such as TP53 abnormalities (ie, TP53 mutation or 17p deletion, or both) or IGHV- Patients with unmutated CLL may not experience durable benefit .
-
Daratumumab may be an effective maintenance strategy after ASCT in NDMM patients
Time of Update: 2022-02-23
RESULTS: Study process and patient characteristics Between May 30, 2016, and June 18, 2018, 886 patients with ≥ partial response (PR) in Part 1 were randomly assigned to daratumumab maintenance therapy ( 442 cases) or observation group (444 cases) (Figure 1) .
-
Safety analysis of dual PI3Kδ/CK1ε inhibitor Umbralisib in patients with relapsed/refractory lymphoma
Time of Update: 2022-02-23
The 4 studies include: The TGR-1202-101 study (NCT01767766) is a Phase I dose-escalation trial evaluating umbralisib in R/R, histologically confirmed hematological malignancies (B-cell NHL, CLL, peripheral T-cell lymphoid safety and efficacy in patients with cancer and HL) .
-
Comments by Prof. Jiajun Liu: Clinical impact of NPM1 mutation after chemotherapy in acute myeloid leukemia
Time of Update: 2022-02-23
In univariate analysis, variables significantly associated with molecular exhaustion were: white blood cell count and FLT3-ITD at diagnosis, chemotherapy courses received, and EOT NPM1mut MRD levels .
-
Express reduced the bleeding rate by 85%, and the long-term effect of the phase 3 clinical trial of hemophilia gene therapy was positive
Time of Update: 2022-02-23
The trial results showed that patients who received a single gene therapy treatment had an 85% reduction in annual bleeding rate (ABR) from baseline after two years of treatment, which was superior to coagulation factor VIII prophylaxis .
-
Based on the present, looking forward to the future, the big coffee talks about the major progress in the field of hemophilia
Time of Update: 2022-02-23
. After that, Professor Wang systematically introduced the development history of hemophilia drugs in detail, from blood-derived products-recombinant products-extended half-life FⅧ-emerizumab, with the advancement of technology, the bleeding control of patients with hemophilia A has been improved.
-
Young female dyspnea on exertion is progressively worsening, what is the most suitable treatment for this patient?
Time of Update: 2022-02-23
Answer: Mediastinal mass biopsy Learning points: For hemodynamically stable mediastinal mass patients with symptoms of superior vena cava syndrome, the initial treatment is biopsy to confirm the diagnosis .
Superior vena cava syndrome causes.
-
In-hospital management of patients with thrombocytopenia due to hematological diseases (6) - Thrombocytopenia due to lymphoma chemotherapy
Time of Update: 2022-02-23
The evaluation and process of lymphoma CIT is similar to leukemia CIT (see In-hospital management of patients with thrombocytopenia due to hematological diseases (5)—thrombocytopenia due to chemotherapy in acute leukemia), but it should be noted that different chemotherapy regimens may cause The incidence of lymphoma CIT is different, such as ICE, AI (doxorubicin, ifosfamide), MAID (doxorubicin, ifosfamide, dacarbazine).
-
The results of the selection of the top ten research progress in China's hematology in 2021 were announced at the 2nd China Hematology Development Conference
Time of Update: 2022-02-23
This study revealed a new mechanism for the maintenance of hematopoietic stem cell function, and laid a theoretical foundation for in-depth exploration of the epitranscriptional regulation mechanism of blood ecology under physiological and pathological conditions .
-
First hemophilia gene therapy coming to market?
Time of Update: 2022-02-23
Recommended reading: Gene therapy for hemophilia A, once rejected by the FDA, is now designated as an advanced therapy for regenerative medicineYimai Meng broke the news Today, BioMarin intends to submit all study participants in the Phase 3 GENER8-1 study in accordance with the FDA’s previous requirements Two-year follow-up safety and efficacy data to support the benefit/risk assessment of valoctocogene roxaparvovec .
-
RACE study results released, eltrombopag combination therapy is expected to become the new standard of treatment for severe aplastic anemia
Time of Update: 2022-02-23
Studies have shown that in patients with severe aplastic anemia, the addition of eltrombopag to IST alone resulted in higher quality and faster remission in patients with SAA/vSAA without increased toxicity .
-
Annual Inventory Professor Huang Wenrong: In the era of new drugs, autologous hematopoietic stem cell transplantation is still unshakable in the treatment of multiple myeloma
Time of Update: 2022-02-23
In recent years, the continuous progress of therapeutic drugs such as proteasome inhibitors, immunomodulators, and monoclonal antibodies has led to a significant improvement in the survival rate of MM patients .
-
Professor Song Yuqin of Lymphoma Academy: Interpretation of the 2021 V5 NCCN Guidelines for Mantle Cell Lymphoma
Time of Update: 2022-02-23
Consider ASCT as a first-line consolidation regimen, and then recommend rituximab for maintenance therapy; non-intensive chemotherapy regimens are recommended for patients who are not suitable for ASCT (NCCN guidelines recommend BR, VR-CAP, R-CHOP, and R2 regimens preferentially) or participate in clinical trials .
-
Annual inventory of 2021 acute lymphoblastic leukemia research progress summary
Time of Update: 2022-02-23
When medical insurance is in progress | Care for ALL: Belintoumumab helps patients with relapsed or refractory acute lymphoblastic leukemia to open the era of immunotherapy 03 Antibody-drug conjugates (ADC) 1.
-
[Wednesday Reading] Professor Liu Qifa: Based on AML, looking forward to the future, comprehensively analyzing the impact of IDH mutation on the development and treatment of AML
Time of Update: 2022-02-23
Combination of demethylating agents in newly diagnosed AML: a phase I/II trial in newly diagnosed IDH1-mutant AML patients showed that ivonib combined with azacitidine induced leukemia cell differentiation and apoptosis with an ORR of 78.
-
Prof. Depei Wu: From nothing, stuximab opens a new chapter in the treatment of Castleman's disease in China
Time of Update: 2022-02-22
In China, stuximab was recently approved for the treatment of HIV-negative, HHV-8-negative adult patients with multicenter Castleman disease .
Depei Wu has combined the current international clinical research on Castleman's disease and found that the comprehensive advantages of stuximab treatment are relatively significant .
-
To treat this blood system disease, TPO receptor agonist is approved for marketing
Time of Update: 2022-02-22
▎WuXi AppTec Content Team Editor Recently, a thrombopoietin (TPO) receptor agonist, roprostim for injection (previously known as romiprostim for injection), was approved by the State Drug Administration of China ( NMPA) approved for marketing for primary immune thrombocytopenia (ITP) .
-
Professor Lai Yongrong: New Progress in Thalassemia Treatment The 2nd China Hematology Development Conference
Time of Update: 2022-02-22
From January 14th to 16th, 2022, the 2nd China Hematology Development Conference will be held online . With the theme of "Strengthening the Foundation, Emphasizing Clinical Practice, and Promoting
-
Professor Li Yuhua & Professor Li Wenyu: Drug accessibility and standardization are synchronized, and otuzumab benefits more B-cell lymphoma patients
Time of Update: 2022-02-22
In the past 15 years, the clinical trials of new anti-lymphoma drugs in China have made great progress, and patients have more treatment options, but their survival still needs to be improved .
-
Lymphoma Interview with Prof. Junning Cao: In the Era of New Drugs, Innovative PI3K Inhibitors Bring Survival Benefits to MZL Patients
Time of Update: 2022-02-22
In recent years, the emergence of new targeted drugs such as Bruton's tyrosine kinase (BTK) inhibitors and phosphatidylinositol 3-kinase (PI3K) inhibitors has shown encouraging clinical efficacy and is expected to further improve R /R MZL patients survive and improve their quality of life .
